Skip to main content

Economic argument for citrate haemofiltration

Introduction

Regional citrate anticoagulation is associated with increased mean filter life and greater completion of scheduled filter life compared with heparin [1]. Studies report mean filter lifespans of 44 hours [2] and that 80% of patients reach 72 hours [3]. The potential cost saving from this reduced filter kit purchase is only realised if the treatment is stopped due to filter clotting and needs to be recommenced. In order to identify this we set out to evaluate the filter life and stopping reason for CVVHF treatment in general critically ill patients.

Methods

One hundred sequential patients receiving CVVHF were identified. For each patient, the number of treatments, filter life and reason for stopping treatment were recorded. A subset of treatments in which stopping was due to filter clotting and therapy resumed was identified. These were then analysed to see how many filtration sets could be saved if the filter life was 44 hours [2]. Sensitivity analysis was performed based on a 50% change in filter life improvement.

Results

A total of 304 filter sets were used in 100 patients (one to 14 per patient) - median duration 18.3 hours (IQR 8.5 to 38.3) (Table 1). Cost analysis demonstrated 75 filters could be saved if filter lives were prolonged to 44 hours, equivalent to €4.01/treatment-hour (€3.26 to €5.03).

Table 1 Treatments by stopping reason

Conclusions

Prolonged filter life associated with citrate CVVHF leads to a potential saving of €4.01/treatment-hour. This information is of benefit when considering the business case for introducing citrate continuous venovenous haemofiltration.

References

  1. 1.

    Bagshaw SM, et al.: J Crit Care. 2005, 20: 155-161. 10.1016/j.jcrc.2005.01.001

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Mehta , et al.: J Am Soc Nephrol. 1993, 4: 368.

    Google Scholar 

  3. 3.

    Slowinski T, et al.: Crit Care. 2010,14(Suppl 1):p518. 10.1186/cc8750

    PubMed Central  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to J Patterson.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Patterson, J., Laba, D. & Blunt, M. Economic argument for citrate haemofiltration. Crit Care 15, P126 (2011). https://doi.org/10.1186/cc9546

Download citation

Keywords

  • Citrate
  • Heparin
  • Cost Saving
  • Cost Analysis
  • Potential Cost